Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
| ▸ | TLR2 | O60603 | 5/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085040 | 1.00 | MEN1 (0.45) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL12085013 | 1.00 | MEN1 (0.45) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL12084915 | 1.00 | MEN1 (0.45) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL13625079 | 0.94 | MEN1 (0.50) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL12085807 | 0.89 | MEN1 (0.45) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL12085116 | 0.89 | MEN1 (0.45) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL13158220 | 0.83 | MEN1 (0.40) | MEN1KMT2AUSP2TSHRGLP1R | |
| SCHEMBL13157948 | 0.82 | GNPAT (0.41) | MEN1KMT2AGLP1RTLR2 | |
| SCHEMBL13010640 | 0.80 | GLP1R (0.42) | MEN1KMT2AGLP1RHPGD | |
| SCHEMBL23177849 | 0.79 | MEN1 (0.46) | MEN1KMT2AUSP2TSHRTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | MEN1 161/4885KMT2A 4044/4885USP2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.